When should patients receive CAR T-cell therapy?
CAR T-cell therapy, a potent but costly and time-intensive cancer treatment with significant immune-related side effects, is generally reserved as a last resort for patients with specific cancers like leukemia and lymphoma who have not responded to other therapies or are ineligible for alternative treatments.
CAR T-cell therapy is a powerful type of cancer treatment that uses modified immune cells to target and attack cancer cells. While potentially life-saving, CAR T-cell therapy is not always the most appropriate treatment. Depending on the circumstance, CAR T-cell therapy may be considered unsafe and reserved only for some patients.
What is a last resort treatment?
Last resort treatments offer benefits at the cost of simultaneous dangers. Treatments that pose more severe health effects may be considered in cases where the mortality rate is considered very high.
CAR T-cell therapy has the potential to produce long-lasting results in some patients, and the treatment has even been shown to lead to complete remission. However, CAR T-Cell therapy is not suitable for every patient. Even though it does not pose sufficiently high risks, it still causes possible effects for some patients. It may only be an option for patients who have not responded to other types of therapies or those who are not eligible for certain treatment types.
CAR T-cell therapy is sometimes understood as a last resort treatment option for patients with specific types of cancer that have not found success with other treatments. The reason is that CAR T-cell therapy is a new treatment only approved for use for only a few cancers, including leukemia and lymphoma.
Disadvantages of CAR T-cell therapies
Another reason why CAR T-cell therapy might be considered a last resort therapy is that it poses several risks. Some of these disadvantages include:
- Cost – CAR T-cell therapy can be prohibitively expensive and is often not covered by many insurance plans.
- Time – CAR T-cell therapy is often considered to be a highly involved treatment, requiring significant time and frequent visits for treatment.
- Side Effects – Like other types of cancer treatment, CAR T-cell therapy poses potential side effects. These side effects typically affect the immune system, potentially causing the immune system to become overactive or toxic to the nervous system, combined with more common side effects, including higher risks of infection and bleeding.
Learn more about how CAR-T cell therapy works.
Related
Comparing CAR T-cell and chemotherapy for cancer treatment
CAR T-cell therapy, a novel immunotherapy modifying patients' T-cells to target cancer cells, shows promising long-lasting remission especially in blood cancers like leukemia and lymphoma, whereas chemotherapy, a widely used drug-based treatment effective across many cancer types but with severe side effects, remains more established, making the choice between them dependent on cancer type, stage, patient health, and treatment response.
What is CAR-T therapy or adoptive cell transfer?
CAR T-cell therapy is a cancer treatment that involves modifying a patient’s T cells in the lab to express chimeric antigen receptors (CARs) that enable the T cells to specifically recognize and attack cancer cells, primarily used for certain blood cancers like B cell lymphoma and leukemia, especially when traditional treatments fail or cancer recurs.
FAQ center
The FAQ center explains that lab automation uses data science to create intelligent systems reducing human input, digital labs fully digitize operations for efficiency, future labs will heavily rely on robotics and integrated data management, lab compliance ensures safe and effective lab practices, data integrity ensures reliable data quality, scientific data management systems (SDMS) facilitate safe and accessible scientific data handling, and open data differs from FAIR data in accessibility and usability requirements.
Biologics Drug Discovery
The Dotmatics Biology Solution offers comprehensive end-to-end data management and analysis tools tailored for biologics drug discovery—including antibodies, CAR-T cells, and RNA therapeutics—facilitating collaborative workflows in molecular cloning, protein production, biologics registration, and assay data analysis to accelerate innovation and streamline complex research processes.
How Growing Demand and Cost Pressures Are Reshaping the Biologics Discovery Landscape
The biologics discovery landscape is being reshaped by growing demand and cost pressures as biologics, including monoclonal antibodies, gene, RNA, and cell therapies, gain momentum with increasing FDA approvals, substantial market growth projected to exceed $700 billion by 2030, and strong investment flows, while innovators face the challenge of delivering novel, cost-effective treatments rapidly amid financial and development complexities.
Chem-Bio Informatics Society (CBI) Annual Meeting 2022
At the Chem-Bio Informatics Society (CBI) Annual Meeting 2022 held on October 25 at Tower Hall Funabori in Tokyo, Dotmatics will present and exhibit their advanced integrated platform that enhances collaboration and automates data handling across diverse chemical and biological modalities to support multimodality drug discovery research, with speakers Zsolt Lepp and Takashi Fukuyama showcasing real-world solutions at booth number 4.